To address this limitation, several strategies have been explored to selectively deliver IFN-α to the tumor itself, including: (1) immunocytokines; (2) genetically modified DCs expressing IFN-α; (3) viral and other tumor-targeting vectors encoding IFN-α [40–43]; and (4) vectors encoding pattern recognition receptor agonists delivered directly into tumor microenvironment. This evidence concerns the gene IFNA2 and neoplasm.